首页> 外文期刊>Nanoscience and nanotechnology research in Catalonia >Pedro Alonso, from theUniversity of Barcelona,selected a solidarity heroby Time magazine
【24h】

Pedro Alonso, from theUniversity of Barcelona,selected a solidarity heroby Time magazine

机译:巴塞罗那大学的佩德罗·阿隆索(Pedro Alonso)被《时代》杂志评选为团结英雄

获取原文
获取原文并翻译 | 示例
       

摘要

Time magazine devoted its cover story of the November 7, 2005 issue to the fight against diseases that affect developing countries. The magazine highlighted the work carried out by 18 "solidarity heroes", as Time called a group made up of physicians, researchers, and non-governmental organizations. Among these heroes is Pedro Alonso, director of the International Health Center of the Hospital Clinic of the University of Barcelona and the International Preventive Treatment of Infants (IPTi, see Contributions to Science [2005] 3:111-112). Alonso leads a research team that has focused its work on the development of a vaccine against malaria, a disease that annually kills 1.5-2.7 million people worldwide Expectations regarding the candidate vaccine currently being tested (RTS.S/AS02A) are quite high. A follow-up of 1442 children who were inoculated in 2003 has shown that the vaccine has retained its efficiency over a 1.5-year period. The RTS.S/AS02A vaccine reduced clinical malaria in 35% of vaccinated individuals, and the severe malaria in 49%. These results, published recently in The Lancet and presented at the Multilateral Initiative on Malaria's Pan-African Malaria Conference, held in Yaounde, Cameroon, in November 2005, are very promising. The vaccination project is a* joint venture of the International Health Center in Barcelona, GlaxoSmithKline (GSK) Bio-logicals, and the Center for Health Research in Manhica, Mozambique, and has received funds from the Bill & Melin-da Gates Foundation.
机译:《时代》杂志将其2005年11月7日期的封面故事专门用于与影响发展中国家的疾病作斗争。该杂志重点介绍了18位“团结英雄”所进行的工作,时代周刊(Time)召集了一个由医生,研究人员和非政府组织组成的小组。巴塞罗那大学医院诊所国际卫生中心主任和婴儿国际预防治疗中心主任佩德罗·阿隆索(Pedro Alonso)就是其中之一(IPTi,请参阅对科学的贡献[2005] 3:111-112)。阿隆索(Alonso)领导着一个研究小组,致力于研究针对疟疾的疫苗,该疾病每年在全球范围内杀死1.5至270万人。对目前正在测试的候选疫苗(RTS.S / AS02A)的期望很高。对2003年接种的1442名儿童进行的跟踪研究表明,该疫苗在1.5年的时间内一直保持其有效性。 RTS.S / AS02A疫苗在35%的疫苗接种者中减少了临床疟疾,在49%的情况下减少了严重疟疾。这些结果最近发表在《柳叶刀》上,并于2005年11月在喀麦隆雅温得举行的关于疟疾的多边倡议泛非疟疾会议上提出,非常有希望。疫苗接种项目是巴塞罗那国际卫生中心,葛兰素史克(GSK)生物逻辑学和莫桑比克曼希卡卫生研究中心的合资项目,并已获得比尔和梅林达·盖茨基金会的资助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号